Nicholas A. Butowski, MD

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Intern, 1999-2000, Medicine
University of California, San Francisco, San Francisco, CA, Fellow, 2003-2005, Neuro-Oncology

• 2000-2003
  Residency in Neurology; Department of Neurology, University of California, San Francisco, CA
• 2003-2004
  Fellow, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
• 2004-2005
  Clinical Instructor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
• 2005-present
  Assistant Clinical Professor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
• 2006-present
  Director of Clinical Services, Dept. of Neurological Surgery, Neuro-Oncology Service, Brain Tumor Research Center, University of California, San Francisco (UCSF)
• 2005-present
  Assoc Member of the Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF
• 2005-present
  Assoc Member of the Comprehensive Cancer Center, UCSF
• 2009-present
  Co-chair, CNS Cancer Program Site Committee
• 2009-present
  Member, UCSF Cancer Program Protocol Review Committee
• 2009-present
  Member, National Comprehensive Cancer Center Network CNS Cancer Guideline Committee

• Butowski N. Immunostimulants for malignant gliomas. Neurosurg Clin N Am. Jan;21(1):53-65.
• Butowski N, Chang SM. Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control. Apr 2005;12(2):116-124.
• Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. Apr 1 2005;61(5):1454-1459.
• Chang SM, Reynolds SL, Butowski N, et al. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. Oct 2005;7(4):425-434.
• Butowski NA, Chang SM. Glial tumors: the current state of scientific knowledge. Clin Neurosurg. 2006;53:106-113.
• Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. Mar 10 2006;24(8):1273-1280.
• Chang SM, Butowski NA, Sneed PK, Garner IV. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus. 2006;20(4):E4.
• Butowski N, Lamborn KR, Berger MS, Prados MD, Chang SM. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol. Oct 2007;85(1):87-94.
• Robins HI, Chang S, Butowski N, Mehta M. Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep. Jan 2007;9(1):66-70.
• Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. Nov 2008;109(5):817-824.
• Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. Jan 2009;91(2):175-182.
• Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. Jan 2009;91(2):183-189.
• Chang SM, Nelson S, Vandenberg S, et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol. May 2009;92(3):401-415.
• Liu R, Solheim K, Polley MY, et al. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. Feb 2009;11(1):59-68.
• Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. Feb 1 2009;27(4):579-584.